Search
SOLACI Congress
HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Structural heart disease

Impella in High Risk Coronary Angioplasty before TAVR

The population is aging, which is closely related with the presence of aortic stenosis. This condition, as...
solaci -
Learn More
Mitral valve

TCT 2023 | CLASP IID Study 1-Year Results: PASCAL vs. MITRACLIP for Degenerative Mitral Regurgitation

The negative impact of mitral regurgitation (MR) on patient mortality, morbidity, and quality of life is widely...
solaci -
Learn More
Structural heart disease

TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus

Degenerative aortic stenosis (AS) is the most common valve condition. A significant number of AS patients presents...
solaci -
Learn More
Mitral valve

TCT 2023 | TRILUMINATE Trial: Health Status after TriClip

Severe tricuspid regurgitation (TR) has been associated with higher mortality, increased risk of hospitalization for cardiac failure...
solaci -
Learn More
Structural heart disease

TCT 2023 | PARTNER 3 Low Risk: 5-Year Follwup

TCT has presented the 5-year clinical and echocardiographic outcomes of low-risk patients with severe aortic stenosis treated...
solaci -
Learn More
Mitral valve

TCT 2023 | EXPAND G4

The EXPAND G4 is a prospective multicenter single arm study on real life patients.  It included a total...
solaci -
Learn More
Structural Heart Disease

TCT 2023 | ALIGN AR Trial

Dr. Thourani has presented the ALIGN AR, a single arm, multicenter and non-blinded trial on the use...
solaci -
Learn More
Structural Heart Disease

TCT 2023 | EVOLUT Low Risk: 4-Year Follow-up

In recent years, there has been a steady increase in the use of transcatheter aortic valve replacement...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy